Eptinezumab may provide sustained reductions in headache days and disability for adults with treatment-resistant chronic migraine.

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant ...

H. Lundbeck A/S (Lundbeck) today announced that new migraine clinical data will be presented at the European Academy of Neurology (EAN) Congress 2026, taking place 27–30 June in Geneva, Switzerland.

LOS ANGELES -- Eptinezumab, an intravenous calcitonin gene-related peptide (CGRP) inhibitor, met its primary endpoint in the phase III PROMISE 2 trial of chronic migraine prevention, reported ...

VALBY, Denmark, Sept. 11, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) is advancing leadership in migraine with a comprehensive collection of datasets to be presented at the 2025 International ...

(HealthDay)—Compared with placebo, treatment with intravenous eptinezumab after onset of a moderate-to-severe migraine attack shortens time to resolution of headache pain and the most bothersome ...

• The one-year INFUSE study observed patient-reported migraine-related cognitive symptoms at baseline and changes over 6 months in those with at least one prior anti-calcitonin gene-related peptide ...

Lundbeck has presented new clinical data on eptinezumab at the 2025 International Headache Congress in São Paulo, highlighting its long-term preventive effectiveness in patients severely affected by ...

at least 3 preventive medicines have not worked, or are not tolerated or are unsuitable because of safety concerns, and the company provides it according to the commercial arrangement. in episodic ...

Patients with chronic migraine and medication-overuse headache represent a specific subset of the migraine patient population who are severely impacted by the condition. These patients are trapped in ...

The recommendations were made after consideration of the evidence submitted by Lundbeck, a review of this submission by the external assessment group (EAG) and submissions from stakeholders. See the ...

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant ...